Get the Stockscreener App
0.1151
2.68%
0.003
After Hours:
.11
-0.0051
-4.43%
Kala Bio Inc stock is traded at $0.1151, with a volume of 1.25M.
It is up +2.68% in the last 24 hours and down -33.43% over the past month.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$0.1121
Open:
$0.1136
24h Volume:
1.25M
Relative Volume:
0.18
Market Cap:
$106.98M
Revenue:
$420.00K
Net Income/Loss:
$-26.98M
P/E Ratio:
-0.0276
EPS:
-4.1721
Net Cash Flow:
$-32.01M
1W Performance:
+5.21%
1M Performance:
-33.43%
6M Performance:
-84.31%
1Y Performance:
-96.66%
1-Day Range:
$0.0996
$0.117
1-Week Range:
$0.0996
$0.1179
52-Week Range:
$0.0996
$20.60
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.1151 | 104.20M | 420.00K | -26.98M | -32.01M | -4.1721 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-29-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-08-25 | Initiated | Mizuho | Outperform |
| Jul-11-25 | Initiated | Ladenburg Thalmann | Buy |
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
symbol__ Stock Quote Price and Forecast - CNN
Kala Bio chases 'Palantir for biotech' dream with new AI platform - MSN
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Kala Bio rises on plans to leverage AI - MSN
Kala Bio Stock Just Plunged 92% Today – Here’s What Happened - MSN
KALA Stock Price, Quote & Chart | KALA BIO INC (NASDAQ:KALA) - ChartMill
KALA BIO (KALA) Stock Volatility | Q3 2025: EPS Tops ViewsElite Trading Signals - Cổng thông tin điện tử tỉnh Lào Cai
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine - ADVFN
KALA BIO, Inc. (NASDAQ:KALA) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
KALA BIO (KALA) Stock Shared Voting (Momentum Fading) 2026-04-20Gap Up Stocks - Xã Thanh Hà
$9.1 Billion Mesenchymal Stem Cell Market by 2031 to be Focused on by New Senior Scientific Advisor for KALA BIO, Inc. (Nasdaq: KALA) - Barchart.com
$9.1 Billion Mesenchymal Stem Cell Market by 2031 to be Focused - openPR.com
Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA) - PRLog
Kala Bio Transitions to AI-Powered Biotech Solutions with Researgency Platform and MSC-S Asset Strategy 47 - Minichart
KALA BIO (NASDAQ:KALA) Posts Quarterly Earnings Results - MarketBeat
KALA BIO: Q4 Earnings Snapshot - Barchart
Eye-drug setback pushes KALA BIO (NASDAQ: KALA) toward high-risk AI bet - Stock Titan
KALA BIO, Inc. (NASDAQ:KALA) Sees Significant Drop in Short Interest - MarketBeat
Should I invest in Palisade Bio Inc before earnings2026 Performance Recap & Expert Curated Trade Setup Alerts - baoquankhu1.vn
What is the bull case for KALA BIO (KALA) Stock | Price at $0.18, Up 0.17%Professional Trade Ideas - Cổng thông tin điện tử tỉnh Lào Cai
Earnings Risk: What is KALA BIO Incs market position2026 Levels & Growth Focused Stock Reports - baoquankhu1.vn
Top 3 Health Care Stocks Which Could Blast Off This Quarter - Benzinga
What do insiders think about KALA BIO (KALA) Stock | Price at $0.17, Up 5.70%Fundamentals - Xã Vĩnh Công
Is KALA BIO (KALA) Stock Showing Strength | Price at $0.17, Up 2.70%Real Trader Insights - Cổng thông tin điện tử tỉnh Lào Cai
Kala Pharmaceuticals Inc (27F0.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
KALA Bio launches on-premises AI platform for biotech sector By Investing.com - Investing.com India
KALA BIO Inc. (KALA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kala Bio engages advisor to review clinical assets, AI analytics By Investing.com - Investing.com South Africa
KALA SEC FilingsKala Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Kala Bio Delays 2025 Annual Report Filing - The Globe and Mail
KALA BIO, Inc. (KALA) stock price, news, quote and history - Yahoo Finance UK
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Kala Bio engages advisor to review clinical assets, AI analytics - Investing.com
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities - manilatimes.net
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and ... - Caledonian Record
Kala Bio (NASDAQ: KALA) notifies SEC of late 2025 10‑K, cites turnover - Stock Titan
Bionic Intelligence Research Agent Now Commercially Live for Secure, Scalable, Autonomous Solutions in Global Biotech and Pharma Industries: KALA BIO, Inc. (Nasdaq: KALA) - Barchart.com
Bionic Intelligence Research Agent Now Commercially Live - openPR.com
User - The Chronicle-Journal
Kala Bio deploys AI research agent for biotech clients By Investing.com - Investing.com South Africa
Kala Bio Announces Initial Commercial Deployment of Bionic Intelligence Research Agent - marketscreener.com
Exclusive: Penny stock Kala Bio transitions to revenue model with AI platform launch - MSN
Kala Bio deploys AI research agent for biotech clients - Investing.com
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live - The Manila Times
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):